Literature DB >> 1313597

Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research.

A Arimura1.   

Abstract

For last 2 years since PACAP was first discovered, many important findings on PACAP have been reported. cDNAs encoding the precursor proteins of PACAP in sheep, human and rat were cloned, and the precursor proteins characterized. PACAP was found in a high concentration in the central nervous system, adrenal medulla and testis. Immunohistochemical study indicated that PACAP containing neural fibers are present throughout the brain, including both internal and external zones of the median eminence. In the hypothalamus many PACAP positive cell bodies were demonstrated in the supraoptic nucleus and the paraventricular nucleus in various species. Four types of high affinity PACAP receptor were demonstrated. PACAP receptors in the central nervous system, pituitary, adrenal medulla and germ cells of the testis are highly specific for PACAP, and not shared with VIP. The PACAP receptor was solubilized and cross-linking of 125I-PACAP27 with the binding protein suggest that the molecular weight of the receptor is around 57,000. Various biological actions of PACAP were reported, but the physiological cellular events linked with PACAP-induced activation of adenylate cyclase remain to be investigated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1313597

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  65 in total

1.  (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.

Authors:  Terry W Moody; Robert T Jensen; Mati Fridkin; Illana Gozes
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

2.  PACAP modulation of the colon-inferior mesenteric ganglion reflex in the guinea pig.

Authors:  Leonid G Ermilov; Philip F Schmalz; Steven M Miller; Joseph H Szurszewski
Journal:  J Physiol       Date:  2004-07-29       Impact factor: 5.182

3.  VIP-PACAP 2010: my own perspective on modulation of cognitive and emotional behavior.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2010-11       Impact factor: 3.444

4.  Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection.

Authors:  Chee Yeun Chung; Hyemyung Seo; Kai Christian Sonntag; Andrew Brooks; Ling Lin; Ole Isacson
Journal:  Hum Mol Genet       Date:  2005-05-11       Impact factor: 6.150

5.  Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene.

Authors:  I Gozes; J Glowa; D E Brenneman; S K McCune; E Lee; H Westphal
Journal:  J Mol Neurosci       Date:  1993       Impact factor: 3.444

6.  PAC1 regulates receptor tyrosine kinase transactivation in a reactive oxygen species-dependent manner.

Authors:  Terry W Moody; Lingaku Lee; Tatiana Iordanskaia; Irene Ramos-Alvarez; Paola Moreno; Howard E Boudreau; Thomas L Leto; Robert T Jensen
Journal:  Peptides       Date:  2018-09-28       Impact factor: 3.750

7.  Glial expression of the proenkephalin gene in slice cultures of the subventricular zone.

Authors:  L Just; C Olenik; D K Meyer
Journal:  J Mol Neurosci       Date:  1998-08       Impact factor: 3.444

8.  PACAP-mediated ATP release from rat urothelium and regulation of PACAP/VIP and receptor mRNA in micturition pathways after cyclophosphamide (CYP)-induced cystitis.

Authors:  Beatrice M Girard; Amanda Wolf-Johnston; Karen M Braas; Lori A Birder; Victor May; Margaret A Vizzard
Journal:  J Mol Neurosci       Date:  2008-06-19       Impact factor: 3.444

9.  Pituitary adenylate cyclase-activating polypeptide: Postnatal development in multiple brain stem respiratory-related nuclei in the rat.

Authors:  Qiuli Liu; Margaret T T Wong-Riley
Journal:  Respir Physiol Neurobiol       Date:  2018-10-22       Impact factor: 1.931

10.  Comparative effects of PACAP and VIP on pancreatic endocrine secretions and vascular resistance in rat.

Authors:  G Bertrand; R Puech; Y Maisonnasse; J Bockaert; M M Loubatières-Mariani
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.